Vericel Co. (NASDAQ:VCEL) Shares Acquired by Moran Wealth Management LLC

Moran Wealth Management LLC increased its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 42.4% in the third quarter, Holdings Channel reports. The firm owned 10,755 shares of the biotechnology company’s stock after acquiring an additional 3,204 shares during the period. Moran Wealth Management LLC’s holdings in Vericel were worth $454,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Advisors Asset Management Inc. increased its position in shares of Vericel by 4.0% in the third quarter. Advisors Asset Management Inc. now owns 16,890 shares of the biotechnology company’s stock worth $714,000 after acquiring an additional 644 shares in the last quarter. Global Alpha Capital Management Ltd. raised its position in Vericel by 60.2% in the third quarter. Global Alpha Capital Management Ltd. now owns 23,383 shares of the biotechnology company’s stock valued at $988,000 after purchasing an additional 8,791 shares during the period. Segall Bryant & Hamill LLC lifted its stake in shares of Vericel by 49.2% during the third quarter. Segall Bryant & Hamill LLC now owns 115,334 shares of the biotechnology company’s stock worth $4,873,000 after purchasing an additional 38,031 shares in the last quarter. Premier Fund Managers Ltd purchased a new stake in shares of Vericel in the third quarter worth about $781,000. Finally, Meeder Asset Management Inc. acquired a new stake in shares of Vericel in the third quarter valued at about $92,000.

Vericel Price Performance

NASDAQ VCEL opened at $59.11 on Friday. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 985.33 and a beta of 1.66. Vericel Co. has a 12 month low of $32.31 and a 12 month high of $60.15. The company’s fifty day moving average price is $46.13 and its two-hundred day moving average price is $47.02.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. As a group, analysts anticipate that Vericel Co. will post 0.13 EPS for the current year.

Insider Activity at Vericel

In related news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. The trade was a 7.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at $443,850. This represents a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,166 shares of company stock valued at $1,200,764. Corporate insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VCEL. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Friday, November 8th. Stephens boosted their target price on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. TD Cowen raised their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.14.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.